drugset / Trial / NCT03140280

Hypomethylating Properties of Freeze-dried Black Raspberries (BRB) in Patients With Myelodysplastic Syndrome or Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN)

NCT03140280 ↗

Phase 2 Completed 23 enrolled Ehab L Atallah
NaSingle-groupOpen-labelTreatment

Summary

This is a phase II, single-group pilot study to evaluate efficacy and methylation. This study's overarching aim is to evaluate the systemic effects of black raspberries in patients with myelodysplastic syndrome or myelodysplastic syndrome/myeloproliferative neoplasm. Twenty-one patients with MDS will be treated with 25 gm (2x/day) of BRB powder taken orally.

Timeline

Start
2017-06-05
Primary completion
2019-06-01
Completion
2021-05-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Freeze-Dried Black Raspberry Powder Unknown 25 g Oral